A surgical technique called NeuroSafe almost doubles the chances that men will retain erectile function after prostate cancer surgery, according to the first large-scale clinical trial of the procedure. Results presented at the 2025 European Association of Urology congress in Madrid and published in Lancet Oncology offer real hope to the hundreds of thousands of men diagnosed with prostate cancer each year who face a painful trade-off between curing their cancer and preserving their quality of life.
At a glance
- NeuroSafe surgery: A technique where surgeons freeze and examine slices of prostate tissue mid-operation to confirm the tumor has been fully removed — allowing them to spare the surrounding nerve tissue if it’s safe to do so.
- Trial results: Among 344 men with no prior erectile dysfunction, only 38% of NeuroSafe patients reported severe erectile dysfunction one year after surgery, compared with 56% of men who received standard surgery.
- Erectile function outcomes: 39% of NeuroSafe patients reported no or only mild erectile dysfunction at one year, nearly double the 23% who reported the same after standard surgery.
How NeuroSafe prostate surgery works
The prostate is surrounded by a thin outer layer threaded with nerves believed to control erectile function. Standard surgery removes the prostate along with that layer to make sure no cancer cells are left behind — a cautious approach that often damages or destroys those nerves in the process.
NeuroSafe takes a different path. Surgeons remove the prostate and then immediately freeze, stain, and examine thin slices of the tissue while the patient is still on the operating table. If the tumor hasn’t reached the outer edge of the prostate, the nerve-containing layer can be left intact. If it has, surgeons remove it — but at least the decision is based on real-time evidence rather than estimation.
Professor Greg Shaw, the trial lead and a consultant urologist at University College London Hospitals NHS Foundation Trust, described the approach as giving surgeons “the certainty they need to spare as many nerves as possible and give men increased hope of recovering their sexual potency after their cancer is surgically removed.”
Why this matters for men with prostate cancer
Prostate cancer is the most common cancer in men in England, with 50,000 new cases diagnosed every year. Globally, nearly 1.5 million men are diagnosed annually and 375,000 die from the disease each year. It disproportionately affects men over 50 and is often detected late because it produces no symptoms in its early stages.
Surgery can be life-saving. But for many men, the prospect of permanent erectile dysfunction is a serious concern that shapes treatment decisions — sometimes leading men to delay or avoid surgery altogether. A technique that meaningfully reduces that risk without compromising cancer control could shift that calculation for a significant number of patients.
Advances in robotic-assisted surgery have already improved surgeons’ precision in prostate procedures, making nerve-sparing operations more feasible. NeuroSafe builds on that capability by adding an intraoperative feedback loop — a real-time tissue check — that removes much of the guesswork that previously forced surgeons toward more aggressive removal.
Part of a broader shift in cancer care
This trial fits into a wider pattern of cancer medicine moving toward treatments that don’t just extend life but protect how that life is lived. Research into precision surgical techniques has been reshaping what’s possible across multiple cancer types, and prostate cancer surgery is catching up.
The five hospitals involved in this trial are all NHS institutions, signaling that this isn’t just experimental medicine confined to private clinics. The Lancet Oncology publication gives the findings strong scientific standing, and the involvement of Prostate Cancer UK in evaluating the results adds credibility from the patient advocacy side.
What still needs to happen
Dr. Matthew Hobbs, director of research at Prostate Cancer UK, called the results promising but flagged key open questions: researchers still need to confirm that NeuroSafe is as effective as standard surgery at achieving a complete cure, and it’s not yet clear which patients are the best candidates for the technique.
The trial measured erectile function at one year, but the full picture of cure rates and recurrence will take more time and follow-up to establish. Rolling the procedure out at scale across the NHS would also present logistical and resourcing challenges that remain unresolved. The one-year results are encouraging; whether the nerve-sparing approach holds up over a decade is still an open question.
For now, though, the evidence is clear: a surgical technique that nearly doubles the odds of preserving erectile function — without requiring men to choose between cancer treatment and quality of life — is a meaningful advance worth watching closely.
Read more
For more on this story, see: The Independent
For more from Good News for Humankind, see:
- U.K. cancer death rates down to their lowest level on record
- Ghana expands marine protected areas at Cape Three Points
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial
Alzheimer’s prevention may have reached a turning point after a landmark trial showed that removing amyloid plaques before symptoms appear can cut the risk of developing the disease by roughly 50%. Researchers at Washington University School of Medicine studied people with rare genetic mutations that make Alzheimer’s nearly inevitable, finding that early, aggressive treatment can genuinely alter the disease’s course. The results, published in The Lancet Neurology, mark the first time any intervention has shown potential to prevent Alzheimer’s from appearing at all, not merely slow its progression. That distinction matters enormously, since amyloid begins accumulating in the brain two…
-
Marie-Louise Eta becomes first female head coach in men’s top-five European leagues
Female head coach Marie-Louise Eta made history on April 11, 2026, when Union Berlin appointed her as interim head coach — becoming the first woman ever to hold a head coaching position in any of men’s top-five European leagues. The Bundesliga club made the move after dismissing Steffen Baumgart, with five matches remaining and real relegation stakes on the line. Eta, 34, had served as assistant coach since 2023 and was already a familiar, trusted presence within the squad. This was no ceremonial gesture — she was handed a survival fight, which is precisely what makes the milestone significant.
-
Renewables hit 49% of global power capacity for the first time
Renewable energy capacity crossed a landmark threshold in 2025, with global installed power surpassing 5,100 gigawatts and representing 49% of all capacity worldwide for the first time in history. The International Renewable Energy Agency reported a single-year addition of 692 gigawatts, led overwhelmingly by solar power, which alone accounted for 75% of new renewable installations. Clean energy now represents 85.6% of all new power capacity added globally, signaling that the transition has moved from aspiration to economic reality. The milestone carries implications beyond climate — nations with strong renewable bases demonstrated measurably greater energy security amid ongoing geopolitical instability.
